1341209-16-2

Upstream product

• 911845-36-8 (2Z)-4-(5-bromo-2-nitrophenoxy)but-2-enyl propionate 
• 1341209-14-0 (Z)-benzyl 4-(4-(benzyloxycarbonylamino)-3-(4-hydroxybut-2-enyloxy)phenyl)piperazine-1-carboxylate 
• 1341209-12-8 (Z)-benzyl 4-(4-(benzyloxycarbonylamino)-3-(4-(propionyloxy)but-2-enyloxy)phenyl)piperazine-1-carboxylate 
• 1341209-10-6 (Z)-4-(2-nitro-5-(piperazin-1-yl)phenoxy)but-2-enyl propionate 

Downstream Products

• 1341209-22-0 benzyl 4-[(3R,3aS)-3-(hydroxymethyl)-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-7-yl]piperazine-1-carboxylate 
• 1341209-24-2 benzyl 4-[(3R,3aS)-3-{[(3-nitrophenylsulfonyl)oxy]methyl}-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-7-yl]piperazine-1-carboxylate 
• 1341209-26-4 benzyl 4-[(3S,3aS)-3-(acetamidomethyl)-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-7-yl]piperazine-1-carboxylate 
• 1341208-44-3 N-{[(3S,3aS)-7-[4-(3-nitrobenzyl)piperazin-1-yl]-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl]methyl}acetamide 
• 1341208-45-4 N-{[(3S,3aS)-7-[4-(2-nitrobenzyl)piperazin-1-yl]-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl]methyl}acetamide 
• 1341209-18-4 benzyl 4-(4-{[(benzyloxy)carbonyl]amino}-3-{[(2R,3S)-3-{[(tert-butyldimethylsilyl)oxy]methyl}oxiran-2-yl]methoxy}phenyl)piperazine-1-carboxylate 
• 1341209-20-8 benzyl 4-[(3R,3aS)-3-{[(tert-butyldimethylsilyl)oxy]methyl}-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-7-yl]piperazine-1-carboxylate 

Relevant academic research and scientific papers

Design, synthesis, and structure-activity relationship studies of highly potent novel benzoxazinyl-oxazolidinone antibacterial agents

A series of novel benzoxazinyl-oxazolidinones bearing nonaromatic heterocycle or aryl groups were designed and synthesized. Their in vitro and in vivo antibacterial activities were investigated. Most of the (3S, 3aS) biaryl benzoxazinyl-oxazolidinones exhibited potent activity against Gram-positive pathogens. SAR trends were observed; a pyridyl C ring was preferable to other 5- or 6-member aryl C rings, while fluorine substitution on the B ring generated derivatives with reduced activity. Various substituent group positions on the pyridyl ring were also evaluated. The resulting compounds displayed excellent activity against linezolid-resistant strains. Compound 45 exhibited excellent in vitro activity, with a MIC value of 0.25-0.5 μg/mL against MRSA and an activity against linezolid-resistant strains of 8-16-fold higher potency than linezolid. In a MRSA systemic infection model, compound 45 displayed an ED 50 5.0 mg/kg, a potency that is nearly 3-fold better than that of linezolid. This compound also showed excellent pharmacokinetic profiles, with a half-life of more than 5 h as well as an oral bioavailability of 81% in rats.